Literature DB >> 26746185

Selective vulnerability in neurodegeneration: insights from clinical variants of Alzheimer's disease.

Niklas Mattsson1, Jonathan M Schott2, John Hardy3, Martin R Turner4, Henrik Zetterberg5.   

Abstract

Selective vulnerability in the nervous system refers to the fact that subpopulations of neurons in different brain systems may be more or less prone to abnormal function or death in response to specific types of pathological states or injury. The concept has been used extensively as a potential way of explaining differences in degeneration patterns and the clinical presentation of different neurodegenerative diseases. Yet the increasing complexity of molecular histopathology at the cellular level in neurodegenerative disorders frequently appears at odds with phenotyping based on clinically-directed, macroscopic regional brain involvement. While cross-disease comparisons can provide insights into the differential vulnerability of networks and neuronal populations, we focus here on what is known about selective vulnerability-related factors that might explain the differential phenotypic expressions of the same disease-in this case, typical and atypical forms of Alzheimer's disease. Whereas considerable progress has been made in this area, much is yet to be elucidated; further studies comparing different phenotypic variants aimed at identifying both vulnerability and resilience factors may provide valuable insights into disease pathogenesis, and suggest novel targets for therapy. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Entities:  

Keywords:  ALZHEIMER'S DISEASE

Mesh:

Year:  2016        PMID: 26746185     DOI: 10.1136/jnnp-2015-311321

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  34 in total

1.  A method for inferring regional origins of neurodegeneration.

Authors:  Justin Torok; Pedro D Maia; Fon Powell; Sneha Pandya; Ashish Raj
Journal:  Brain       Date:  2018-03-01       Impact factor: 13.501

Review 2.  Don't forget astrocytes when targeting Alzheimer's disease.

Authors:  Jessica S Sadick; Shane A Liddelow
Journal:  Br J Pharmacol       Date:  2019-02-19       Impact factor: 8.739

Review 3.  Applying fluid biomarkers to Alzheimer's disease.

Authors:  Henrik Zetterberg
Journal:  Am J Physiol Cell Physiol       Date:  2017-04-19       Impact factor: 4.249

4.  Generating Cell Type-Specific Protein Signatures from Non-symptomatic and Diseased Tissues.

Authors:  Jessica S Sadick; Lorin A Crawford; Harry C Cramer; Christian Franck; Shane A Liddelow; Eric M Darling
Journal:  Ann Biomed Eng       Date:  2020-04-17       Impact factor: 3.934

5.  Risk Factors, Neuroanatomical Correlates, and Outcome of Neuropsychiatric Symptoms in Alzheimer's Disease.

Authors:  Stéphane P Poulin; David Bergeron; Bradford C Dickerson
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

Review 6.  Posterior Cortical Atrophy.

Authors:  Jonathan M Schott; Sebastian J Crutch
Journal:  Continuum (Minneap Minn)       Date:  2019-02

7.  Reducing Endogenous α-Synuclein Mitigates the Degeneration of Selective Neuronal Populations in an Alzheimer's Disease Transgenic Mouse Model.

Authors:  Brian Spencer; Paula A Desplats; Cassia R Overk; Elvira Valera-Martin; Robert A Rissman; Chengbiao Wu; Michael Mante; Anthony Adame; Jazmin Florio; Edward Rockenstein; Eliezer Masliah
Journal:  J Neurosci       Date:  2016-07-27       Impact factor: 6.167

Review 8.  Neuropathological assessment of the Alzheimer spectrum.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2020-08-01       Impact factor: 3.575

Review 9.  Propagation and spread of pathogenic protein assemblies in neurodegenerative diseases.

Authors:  Mathias Jucker; Lary C Walker
Journal:  Nat Neurosci       Date:  2018-09-26       Impact factor: 24.884

Review 10.  Selective vulnerability in neurodegenerative diseases.

Authors:  Hongjun Fu; John Hardy; Karen E Duff
Journal:  Nat Neurosci       Date:  2018-09-24       Impact factor: 24.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.